Glioblastoma Tumor Treating Fields Therapy Market

Newly diagnosed glioblastoma leads the glioblastoma tumor treating fields therapy market with a 69.2% share in 2026, followed by adult patients at 62.9%, hospitals at 39.1%, and tumor treating fields systems at 32.5%. Adoption depends on maintenance-stage treatment, specialist coordination, patient adherence, and sustained home-based therapy support.